NEOS S&P 500 High Income ETF vs 22nd Century Group Inc — how do they compare? NEOS S&P 500 High Income ETF trades at $53.41, while 22nd Century Group Inc trades at $4.25 (market cap $1.49M). Which is the better fit depends on your goals.
| SPYI | XXII | |
|---|---|---|
Sector | Income / Options Overlay | Technology |
52-Week High | $54.07 | $1.07K |
52-Week Low | $47.98 | $3.90 |
Market Cap | — | $1.49M |
Enterprise Value | — | -$6.74M |
Signals from Pluang's Aura AI — not financial advice
SPYI, the NEOS S&P 500 High Income ETF, trades at $53.01, down 0.11% on the day. The technical outlook is bearish based on moving averages, with neutral oscillators. The fund has surpassed $10 billion in assets under management and delivers consistent monthly distributions, with a yield around 12%. Recent news highlights its appeal for income-focused investors seeking S&P 500 exposure with lower volatility.
The outlook for SPYI is supported by strong investor demand for high-yield income solutions, though the bearish technical signal and reliance on options strategies present risks. The fund's ability to generate income without significant NAV erosion remains a key advantage in volatile markets.
XXII trades at $4.32, down 0.23% with bearish technical signals. The company shows negative profitability with -65.76% net income margin and -130.19% ROE, though valuation ratios appear low with P/S of 0.03. Recent corporate actions include a 20:1 reverse stock split in June 2026. The company is expanding VLN product distribution in key markets including California and New York, supported by positive FDA regulatory developments.
While analyst consensus is 75% buy-rated, fundamental challenges persist with consistent revenue declines and negative cash flow from operations. Investment opportunity lies in successful VLN brand expansion and regulatory approvals, but risks include ongoing losses, competitive tobacco market pressures, and execution uncertainty in scaling reduced-nicotine products.
Trailing returns across standard periods
Latest headlines on both assets
SPYI is an actively managed ETF designed to generate high monthly income through a data-driven call option strategy on the S&P 500 Index. Unlike traditional covered call funds that often forfeit significant upside, SPYI utilizes a 'call spread' approach—selling near-the-money calls while buying out-of-the-money calls—to capture a portion of equity appreciation in rising markets. It prioritizes tax efficiency by utilizing Section 1256 contracts and tax-loss harvesting to provide investors with high-yield monthly distributions.
Read more on SPYI →22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →